Back to results
US 10,369,131 B2Granted
Ultrapure tetrahydrocannabinol-11-oic acids
AssigneeCorbus Pharmaceuticals, Inc.
InventorsMark Tepper, Dean A. Frey, David Goeddel, Karl E. Reineke
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCorbus Pharmaceuticals, Inc.
InventorsMark Tepper, Dean A. Frey, David Goeddel, Karl E. Reineke
Estimating the term…
This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, Dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.
A method of ameliorating one or more symptoms of an inflammatory disease in a subject in need thereof, wherein the inflammatory disease is dermatomyositis, the method comprising administering to the subject a pharmaceutical composition comprising one or more cannabinoids, wherein said one or more cannabinoids comprise at least 98% (w/w) (6aR,10aR)-3-(1′,1′-dimethylheptyl)-Δ8-tetrahydro-cannabinol-9-carboxylic acid (ajulemic acid), or a pharmaceutically acceptable salt thereof, and wherein no significant antinociception is observed in a hot plate test of mice following oral administration to the mice of 10 mg/kg of said one or more cannabinoids.
Dependencies are inferred from the claim text.